Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Phase 2positiveNamodenosonPositive

AI Analysis

Summary

Can-Fite BioPharma announced positive Phase 2a results for Namodenoson in advanced pancreatic cancer, achieving the primary safety endpoint and demonstrating durable survival outcomes.

Clinical Trial Data

Phase

Phase 2a

Primary Endpoint

Met

Outcome Details

Achieved primary safety endpoint and demonstrated durable survival outcomes in advanced pancreatic cancer

Importance:6/10

Sentiment:

0.75

Phase 2aPancreatic CancerSafety EndpointSurvival DataOncology

Related Companies

$CANF

Read the original article

Published by yahoo_finance on July 1, 2026 11:00 AM

Read Original